Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836414 | 1.00 | CA1 (0.64) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4836421 | 1.00 | CA1 (0.64) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4668694 | 0.92 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL8114468 | 0.92 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4265169 | 0.92 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL7581853 | 0.92 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL7582347 | 0.87 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL7572323 | 0.87 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL9184801 | 0.86 | CA1 (0.60) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL20530493 | 0.86 | CA1 (0.60) | CA1CA2CA7CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468448-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1589018-A1 | PROCESS FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE, INTERMEDIATE THEREOF AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-6867321-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0583171-B1 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | TAKASAGO PERFUMERY CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | CA1 3918/4885CA2 3623/4885CA7 2333/4885 |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | CA1 3927/4885CA2 3610/4885CA7 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.